This Plain Language Summary of Publication from Future Oncology summarises results from the 5-year update from the first part of the COLUMBUS study. The study looked at the combination treatment of encorafenib plus binimetinib in people with a specific type of skin cancer called melanoma. The 5-year update determines whether the mutant melanoma has spread to other parts of the body and whether those who took encorafenib plus binimetinib were alive for longer without their disease getting worse compared to another treatment combination.
Read the full article here.
The original article on which this summary is based was published in the Journal of Clinical Oncology. The original article is called ‘COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600–Mutant Melanoma’. You can read it here.